NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) (www.novabaypharma.com) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide® family of compounds, which are designed to fight infections without causing drug resistance.
The patent will cover compositions of matter and methods of use for NVC-612 and related compounds, all of which have a unique mechanism of action toward microorganisms.This new patent complements NovaBay's existing collection of more than 20 patents and pending patent applications on its proprietary technology platforms. NovaBay holds a patent for its lead anti-infective compound, NVC-422, and has a license to a broad portfolio of pending patent applications covering N-Chlorotaurine (NCT), the naturally occurring antimicrobial molecule from which NovaBay's technology is derived. NVC-422 is currently being studied in four Phase 2 clinical trials for conjunctivitis (Pink Eye), the skin infection impetigo, catheter-associated urinary tract infection, and acne.
"This latest patent will further protect NovaBay's intellectual property, as the company expands its pipeline of first-in-class non-antibiotic anti-infectives to address additional indications," said Dr. Mark Anderson, Chief Scientific Officer. "NovaBay's Aganocide compounds for treating non-systemic, topical infections are designed to rapidly fight infection without causing drug-resistance. This is increasingly important as resistance to antibiotics is becoming a growing public health concern worldwide."
SOURCE NovaBay Pharmaceuticals, Inc.